Funder: Breakthrough T1D
Due Dates: October 31, 2024 (Letter of Intent) | January 7, 2025 (Full proposal)
Funding Amounts: Up to $2,000,000 over 3 years for clinical trials; up to $1,000,000 over 3 years for non-interventional studies; 10% indirect cost cap (SRAs).
Summary: Supports clinical trials and mechanistic studies of metabolic therapies to improve outcomes for people with established type 1 diabetes, emphasizing approaches beyond insulin.
Key Information: LOI is required before full proposal; no citizenship or geographic restrictions; both academic and industry applicants eligible.